Zymeworks (ZYME) PT Lowered to $18 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts ZYME Hot Sheet
Price: $28.37 +0.53%
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 56
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 56
Join SI Premium – FREE
JPMorgan analyst Jessica Fye lowered the price target on Zymeworks (NYSE: ZYME) to $18.00 (from $32.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Zymeworks (ZYME) Reiterated at Market Outperform by Citizens
- Zymeworks ZW191 shows 64.5% response rate in ovarian cancer trial
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
